Crinetics Pharmaceuticals, Inc. (CRNX): The Biotech Stock With Biggest Upside Potential
While Crinetics Pharmaceuticals (NASDAQ:CRNX) Shareholders Have Made 75% in 3 Years, Increasing Losses Might Now Be Front of Mind as Stock Sheds 27% This Week
Oppenheimer Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $73
H.C. Wainwright Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $81
A Quick Look at Today's Ratings for Crinetics(CRNX.US), With a Forecast Between $55 to $92
Express News | Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
